Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Botanix Pharmaceuticals Limited ( (AU:BOT) ).
Botanix Pharmaceuticals announced the immediate resignation of Mr. Matthew Callahan from the Board due to medical reasons. The company expressed gratitude for his contributions and anticipates his return. This change comes as Botanix continues to grow as a sustainable commercial organization, with its FDA-approved product, Sofdra, positioning it strongly in the dermatology market.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for Sofdra, a novel treatment for primary axillary hyperhidrosis, marking it as the first new chemical entity approved for this condition.
Average Trading Volume: 10,516,008
Technical Sentiment Signal: Hold
Current Market Cap: A$742.5M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.